Furthermore, a comprehensive predictive model based on HLA LOH, PD-L1, TMB and CD8+ T cells was constructed, and its association with clinical responses to ICIs was characterized, which may help clinical decision-making in non-small cell lung cancer (NSCLC) patients treated with ICIs. This evidence concerns the gene CD8A and non-small cell lung carcinoma.